Newly approved cancer drugs go untested

The FDA regularly approves costly, toxic drugs that do not improve survival, according to new US research.

Published in JAMA Internal Medicine, the study by two oncologists from Oregon Health and Sciences University looks at data from all cancer drugs approved by the FDA from 2008 to 2012.

Around two thirds were approved on the basis of surrogate endpoints only, generally tumour response